Kiniksa Pharmaceuticals (NASDAQ:KNSA) Rating Reiterated by Wedbush

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report)'s stock had its "outperform" rating reissued by Wedbush in a research report issued to clients and investors on Tuesday, RTT News reports. They currently have a $30.00 target price on the stock. Wedbush's price objective would indicate a potential upside of 69.68% from the company's current price.

Separately, TheStreet upgraded Kiniksa Pharmaceuticals from a "d+" rating to a "c" rating in a research note on Thursday, February 29th.

Kiniksa Pharmaceuticals Trading Up 3.4 %

Shares of KNSA traded up $0.59 during trading hours on Tuesday, hitting $17.68. 611,398 shares of the stock traded hands, compared to its average volume of 402,732. Kiniksa Pharmaceuticals has a 1-year low of $10.65 and a 1-year high of $22.09. The firm has a market capitalization of $1.25 billion, a PE ratio of 98.23 and a beta of 0.27. The business has a fifty day moving average of $19.36 and a 200-day moving average of $18.00.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.15. Kiniksa Pharmaceuticals had a negative return on equity of 6.12% and a net margin of 5.11%. The company had revenue of $83.40 million during the quarter, compared to analysts' expectations of $72.31 million. As a group, equities research analysts expect that Kiniksa Pharmaceuticals will post -0.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Sanj K. Patel sold 12,742 shares of Kiniksa Pharmaceuticals stock in a transaction on Monday, March 4th. The stock was sold at an average price of $21.49, for a total value of $273,825.58. Following the transaction, the chief executive officer now owns 70,594 shares in the company, valued at approximately $1,517,065.06. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 5,126 shares of the business's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $21.79, for a total transaction of $111,695.54. Following the completion of the sale, the chief accounting officer now directly owns 17,588 shares of the company's stock, valued at approximately $383,242.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sanj K. Patel sold 12,742 shares of the business's stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.49, for a total value of $273,825.58. Following the completion of the transaction, the chief executive officer now owns 70,594 shares in the company, valued at approximately $1,517,065.06. The disclosure for this sale can be found here. Insiders have sold a total of 33,109 shares of company stock worth $709,929 in the last 90 days. Company insiders own 54.23% of the company's stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC lifted its position in shares of Kiniksa Pharmaceuticals by 18.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 61,106 shares of the company's stock worth $1,206,000 after acquiring an additional 9,490 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in Kiniksa Pharmaceuticals by 29.2% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 124,878 shares of the company's stock valued at $2,464,000 after acquiring an additional 28,237 shares during the last quarter. Opaleye Management Inc. bought a new position in Kiniksa Pharmaceuticals in the fourth quarter valued at $640,000. Parkman Healthcare Partners LLC increased its stake in Kiniksa Pharmaceuticals by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 615,693 shares of the company's stock valued at $10,799,000 after acquiring an additional 105,883 shares during the last quarter. Finally, Granahan Investment Management LLC increased its stake in Kiniksa Pharmaceuticals by 35.2% in the fourth quarter. Granahan Investment Management LLC now owns 722,388 shares of the company's stock valued at $12,671,000 after acquiring an additional 188,174 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.